ELEDON PHARMACEUTICALS ($ELDN) posted quarterly earnings results for Q4 2025 on Thursday, March 19th. The company reported earnings of -$0.10 per share, beating estimates of -$0.21 by $0.11. The company also reported revenue of $0, equaling estimates of $0 by $0.
Stock price change since market close: +4.56%
You can see Quiver Quantitative's $ELDN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ELEDON PHARMACEUTICALS Hedge Fund Activity
We have seen 59 institutional investors add shares of ELEDON PHARMACEUTICALS stock to their portfolio, and 50 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 3,566,338 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $5,385,170
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 2,600,498 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $6,735,289
- SIREN, L.L.C. removed 2,072,767 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,129,878
- ADAR1 CAPITAL MANAGEMENT, LLC added 1,821,812 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,750,936
- JEFFERIES FINANCIAL GROUP INC. added 1,580,625 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,386,743
- WELLINGTON MANAGEMENT GROUP LLP removed 1,283,939 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,938,747
- ENSIGN PEAK ADVISORS, INC added 1,200,000 shares (+94.9%) to their portfolio in Q4 2025, for an estimated $1,812,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ELEDON PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ELDN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 11/18/2025
To track analyst ratings and price targets for ELEDON PHARMACEUTICALS, check out Quiver Quantitative's $ELDN forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
